Src family kinases and HER2 interactions in human breast cancer cell growth and survival

被引:160
|
作者
Belsches-Jablonski, AP
Biscardi, JS
Peavy, DR
Tice, DA
Romney, DA
Parsons, SJ
机构
[1] Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA
[2] Univ Virginia, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA
[3] Lynchburg Coll, Biol Program, Lynchburg, VA 24501 USA
关键词
Src family kinases; heregulin; breast cancer; HER2/neu; cell growth; apoptosis;
D O I
10.1038/sj.onc.1204205
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Evidence from murine fibroblast models and human breast cancer cells indicates that c-Src and human EGF receptor (HER1) synergize to enhance neoplastic growth of mammary epithelial cells, To investigate whether interactions between c-Src and other HER members may also play a role in breast tumor progression, we characterized 13 human breast carcinoma cell lines and 13 tumor samples for expression of HER family members and c-Src and examined a subset of the cell lines for Src-dependent, heregulin (HRG)-augmented, anchorage-dependent and independent growth. By immunoblotting, we found that all cell lines overexpressed one or more HER family member, and 60% overexpressed c-Src, Seventy-five per cent of the tumor tissues overexpressed HER2, while 64% overexpressed c-Src, Colony formation in soft agar was enhanced by HRG in three of five cell lines tested, a response that correlated,vith the presence of a c-Src/HER2 heterocomplex, This result suggests that HRG may act through both HER2 and c-Src to facilitate anchorage-independent growth. In contrast, HRG had little effect on anchorage-dependent growth in any of the cell lines tested. PP1, a Src family kinase inhibitor, reduced or ablated HRG-dependent and independent soft agar growth or anchorage dependent growth, and triggered apoptosis in all cell lines tested. The apoptotic effect of PP1 could be partially or completely reversed by HRG, depending on the cell line. These results suggest that while Src family kinases may cooperate with HRG to promote the survival and growth of human breast tumor cells, they also function independently of HER2/HRG in these processes.
引用
收藏
页码:1465 / 1475
页数:11
相关论文
共 50 条
  • [41] Estimating scenarios for survival time in patients with HER2 positive, metastatic breast cancer starting HER2 targeted therapies
    Vasista, A.
    Stockler, M.
    West, T.
    Wilcken, N.
    Kiely, B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S216 - S216
  • [42] Poor Survival Outcomes in Elderly HER2 Positive Breast Cancer Patients
    Tovey, S. M.
    Edwards, J.
    Brown, S.
    Mallon, E.
    Doughty, J.
    CANCER RESEARCH, 2009, 69 (24) : 595S - 595S
  • [43] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Chen, Zhaoxu
    Jia, Huiqing
    Zhang, Huina
    Chen, Lifang
    Zhao, Peng
    Zhao, Jing
    Fu, Guangming
    Xing, Xiaoming
    Li, Yujun
    Wang, Chengqin
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (02) : 313 - 323
  • [44] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Zhaoxu Chen
    Huiqing Jia
    Huina Zhang
    Lifang Chen
    Peng Zhao
    Jing Zhao
    Guangming Fu
    Xiaoming Xing
    Yujun Li
    Chengqin Wang
    Breast Cancer Research and Treatment, 2023, 202 : 313 - 323
  • [45] Src family kinases mediate PI3K-Akt pathway activation and resistance to lapatinib in HER2-overexpressing human breast cancer cells
    Rexer, Brent
    Chakrabarthy, Anindita
    Rinehart, Cammie
    Hill, Salisha
    Olivares, Maria
    Ham, Amy
    Liebler, Daniel C.
    Arteaga, Carlos L.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [46] Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2)
    Seyedmirzaei, Homa
    Keshavarz-Fathi, Mahsa
    Razi, Sepideh
    Gity, Masoumeh
    Rezaei, Nima
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (05) : 1235 - 1244
  • [47] An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer
    Elshazly, Ahmed M.
    Gewirtz, David A.
    CANCER DRUG RESISTANCE, 2022, 5 (02) : 472 - 486
  • [48] Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges
    Laokulrath, Natthawadee
    Gudi, Mihir
    Salahuddin, Syed Ahmed
    Chong, Angela Phek Yoon
    Ding, Cristine
    Iqbal, Jabed
    Leow, Wei Qiang
    Tan, Benjamin Yongcheng
    Tse, Gary
    Rakha, Emad
    Tan, Puay Hoon
    HISTOPATHOLOGY, 2024, 85 (03) : 371 - 382
  • [49] Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
    Kim, Min Chong
    Kang, Su Hwan
    Choi, Jung Eun
    Bae, Young Kyung
    JOURNAL OF BREAST CANCER, 2020, 23 (05) : 484 - 497
  • [50] A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer
    Nixon, N. A.
    Hannouf, M. B.
    Verma, S.
    EUROPEAN JOURNAL OF CANCER, 2018, 89 : 72 - 81